The Trump administration on Monday introduced a second group of pharmaceutical firms had pledged to decrease drug costs to ranges akin to these in different nations.
However the particulars of the offers, which President Trump has touted from the White Home as one of the vital essential breakthroughs in well being care, aren’t public. Some key questions stay — together with whether or not all the businesses within the second wave would keep away from tariffs or in any other case obligatory Medicare drug pricing pilot applications. (The White Home didn’t reply to requests for remark about these questions.)
Listed below are among the greatest questions concerning the agreements.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day intelligence on Capitol Hill and the life sciences trade — by subscribing to STAT+.
Have already got an account? Log in
View All Plans
